Form 4: JNJ Executive Exercises Options, Sells Shares

Johnson & Johnson EVP John C. Reed exercised stock options and sold common stock totaling 21,721 shares under a 10b5-1 plan.

Summary

• John C. Reed, Executive Vice President of Innovative Medicine, R&D at Johnson & Johnson (JNJ), executed transactions on October 17, 2025.
• Exercised 21,721 employee stock options at an exercise price of $157.92 per share.
• Simultaneously sold 21,721 shares of common stock at a weighted average price of $192.7072 per share.
• The transactions were conducted pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following these transactions, John C. Reed directly beneficially owns 10,658 shares of common stock and 43,442 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale following option exercise, indicating the executive monetized a portion of their compensation. While a sale, it's part of a 10b5-1 plan and not necessarily indicative of negative sentiment towards the company's future. The profit from the exercise and sale is positive for the executive.

Positives

• The executive realized a profit by selling shares at a weighted average price of $192.7072, significantly higher than the option exercise price of $157.92.
• The transaction was executed under a Rule 10b5-1 plan, indicating pre-planned sales and reducing concerns about opportunistic timing.

Negatives

• The executive sold 21,721 shares, representing a reduction in direct common stock ownership following the option exercise.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the vesting schedule of the stock options, which vest in three equal annual installments beginning on the first anniversary of the grant date.

Management Comments

• The reporting person undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

This Form 4 filing details an executive's routine compensation-related stock transactions, which is common across publicly traded companies. It does not provide specific insights into broader industry trends or competitive positioning for Johnson & Johnson.

Comparison to Industry Standards

• This filing reports an insider transaction, a standard disclosure requirement for executives of publicly traded companies.
• The exercise of stock options and subsequent sale of shares is a common practice for executive compensation and liquidity management, consistent with practices observed in other large pharmaceutical and consumer health companies like Pfizer, Merck, or Procter & Gamble.
• No specific project or company results are comparable in this type of filing, as it pertains to individual executive stock activity.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock ownership and compensation monetization. The sale itself does not directly impact company operations or financial performance.
• Employees: No direct impact on general employees, but relevant for those participating in similar long-term incentive plans.

Next Steps

• The remaining employee stock options will continue to vest in three equal annual installments beginning on the first anniversary of their grant date.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where an executive exercised stock options and sold a portion of the acquired shares, likely for personal financial planning, as indicated by the Rule 10b5-1 plan. Such transactions are common and typically do not signal a change in the company's fundamental outlook or warrant a change in investment recommendation. The executive still retains a significant number of options and shares, suggesting continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter the investment thesis for Johnson & Johnson.

Keywords

Johnson & Johnson, JNJ, Insider Trading, Form 4, Stock Options, Executive Compensation, Share Sale, John C. Reed, 10b5-1 Plan